Switch theme
Sign up to access all valuation multiples
Medigen Vaccine Biologics Corp is a biopharmaceutical company focusing on developing and producing vaccines and biologics. It is engaged in developing IP-protected cell-culture technologies for vaccine manufacturing. The company develops vaccines and affordable biosimilars to prevent regional infectious diseases. The group generates revenue from manufacturing and selling a range of COVID-19 vaccines and COVID-19 test kits and provides technical services on cellular therapy product quality and cell culture tests.
2012
129
LTM Revenue $21.4M
LTM EBITDA $3.3M
$515M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Medigen Vaccine Biologics has a last 12-month revenue (LTM) of $21.4M and a last 12-month EBITDA of $3.3M.
In the most recent fiscal year, Medigen Vaccine Biologics achieved revenue of $20.2M and an EBITDA of $2.5M.
Medigen Vaccine Biologics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Medigen Vaccine Biologics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $21.4M | XXX | $20.2M | XXX | XXX | XXX |
| Gross Profit | $14.8M | XXX | $13.2M | XXX | XXX | XXX |
| Gross Margin | 69% | XXX | 65% | XXX | XXX | XXX |
| EBITDA | $3.3M | XXX | $2.5M | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 12% | XXX | XXX | XXX |
| EBIT | -$2.3M | XXX | -$4.9M | XXX | XXX | XXX |
| EBIT Margin | -11% | XXX | -24% | XXX | XXX | XXX |
| Net Profit | -$0.5M | XXX | -$2.7M | XXX | XXX | XXX |
| Net Margin | -2% | XXX | -13% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Medigen Vaccine Biologics's stock price is TWD 52 (or $2).
Medigen Vaccine Biologics has current market cap of TWD 17.0B (or $566M), and EV of TWD 15.4B (or $515M).
See Medigen Vaccine Biologics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $515M | $566M | XXX | XXX | XXX | XXX | $-0.00 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Medigen Vaccine Biologics has market cap of $566M and EV of $515M.
Medigen Vaccine Biologics's trades at 25.5x EV/Revenue multiple, and 206.2x EV/EBITDA.
Equity research analysts estimate Medigen Vaccine Biologics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Medigen Vaccine Biologics has a P/E ratio of -1068.4x.
See valuation multiples for Medigen Vaccine Biologics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $566M | XXX | $566M | XXX | XXX | XXX |
| EV (current) | $515M | XXX | $515M | XXX | XXX | XXX |
| EV/Revenue | 24.0x | XXX | 25.5x | XXX | XXX | XXX |
| EV/EBITDA | 156.6x | XXX | 206.2x | XXX | XXX | XXX |
| EV/EBIT | -223.5x | XXX | -106.0x | XXX | XXX | XXX |
| EV/Gross Profit | 34.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1068.4x | XXX | -210.8x | XXX | XXX | XXX |
| EV/FCF | 454.8x | XXX | 2673.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMedigen Vaccine Biologics's last 12 month revenue growth is 8%
Medigen Vaccine Biologics's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Medigen Vaccine Biologics's rule of 40 is -246% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Medigen Vaccine Biologics's rule of X is 36% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Medigen Vaccine Biologics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Growth | 155% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -246% | XXX | 20% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 36% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 37% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 37% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 90% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Medigen Vaccine Biologics acquired XXX companies to date.
Last acquisition by Medigen Vaccine Biologics was XXXXXXXX, XXXXX XXXXX XXXXXX . Medigen Vaccine Biologics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Medigen Vaccine Biologics founded? | Medigen Vaccine Biologics was founded in 2012. |
| Where is Medigen Vaccine Biologics headquartered? | Medigen Vaccine Biologics is headquartered in Taiwan. |
| How many employees does Medigen Vaccine Biologics have? | As of today, Medigen Vaccine Biologics has 129 employees. |
| Is Medigen Vaccine Biologics publicy listed? | Yes, Medigen Vaccine Biologics is a public company listed on ROCO. |
| What is the stock symbol of Medigen Vaccine Biologics? | Medigen Vaccine Biologics trades under 6547 ticker. |
| When did Medigen Vaccine Biologics go public? | Medigen Vaccine Biologics went public in 2015. |
| Who are competitors of Medigen Vaccine Biologics? | Similar companies to Medigen Vaccine Biologics include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
| What is the current market cap of Medigen Vaccine Biologics? | Medigen Vaccine Biologics's current market cap is $566M |
| What is the current revenue of Medigen Vaccine Biologics? | Medigen Vaccine Biologics's last 12 months revenue is $21.4M. |
| What is the current revenue growth of Medigen Vaccine Biologics? | Medigen Vaccine Biologics revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of Medigen Vaccine Biologics? | Current revenue multiple of Medigen Vaccine Biologics is 24.0x. |
| Is Medigen Vaccine Biologics profitable? | Yes, Medigen Vaccine Biologics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Medigen Vaccine Biologics? | Medigen Vaccine Biologics's last 12 months EBITDA is $3.3M. |
| What is Medigen Vaccine Biologics's EBITDA margin? | Medigen Vaccine Biologics's last 12 months EBITDA margin is 15%. |
| What is the current EV/EBITDA multiple of Medigen Vaccine Biologics? | Current EBITDA multiple of Medigen Vaccine Biologics is 156.6x. |
| What is the current FCF of Medigen Vaccine Biologics? | Medigen Vaccine Biologics's last 12 months FCF is $1.1M. |
| What is Medigen Vaccine Biologics's FCF margin? | Medigen Vaccine Biologics's last 12 months FCF margin is 5%. |
| What is the current EV/FCF multiple of Medigen Vaccine Biologics? | Current FCF multiple of Medigen Vaccine Biologics is 454.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
